Azenta reports fourth quarter and full year fiscal 2024 results; announces the plan to sell b medical systems and appoints lawrence y. lin as cfo

Fy'24 revenue growth of 4%, reported and organic, in combined sample management solutions and multiomics fy'25 organic revenue growth expected to be 3% to 5% year over year, with adjusted ebitda margin expansion of approximately 300 basis points pursuing a sale of b medical systems to simplify portfolio and drive revenue growth and profitability announces appointment of lawrence y. lin as chief financial officer; herman cueto to remain as advisor to ensure smooth transition burlington, mass.
AZTA Ratings Summary
AZTA Quant Ranking